Posted by Michael Wonder on 02 May 2025
Pfizer’s ALK lung cancer drug Lorviqua lands first-line reimbursement in Korea
2 May 2025 - Pfizer Korea has secured reimbursement for Lorviqua (lorlatinib) as a first-line treatment for ALK-positive metastatic non-small cell lung cancer, a move that could expand access for younger, non-smoking patients facing high risk of brain metastasis.
The greenlight took effect Thursday and came three years after Korea approved the third-generation ALK inhibitor for use in newly diagnosed patients. Until now, the lack of reimbursement meant many couldn’t afford the therapy despite its proven edge over older drugs like crizotinib.
